Cancer Research

Pancreatic cancer
#Cancer research #Pancreatic cancer #Tumours

Benzaldehyde halts the growth of pancreatic cancer

Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer. By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy… Read More

#Cancer Research #News

Bone cancer
#Immunotherapy #Oncology #OS Therapies #Osteosarcoma #Phase II trial #Rare disease

One-year event free survival reported at osteosarcoma conference

OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma.  The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More

#Cancer Research #News

Patients receiving chemotherapy
#Biomarkers #Chemotherapy #Chemotherapy-resistance #Oncology #Tailor Bio

Biomarkers for chemo resistance unlock path to targeted therapies

Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.  The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer… Read More

#Cancer Research #Editor's Choice #News

Prostate cancer cells
#Archeus Technologies #FDA #Oncology #Phase I trial #Prostate cancer #Radiopharmaceuticals

FDA clears radiopharmaceutical for prostate cancer

The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with… Read More

#Cancer Research #News #Regulatory

#Cancer vaccines #Corner Therapeutics #Immunology

In Conversation With: Professor Jonathan Kagan

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Professor Jonathan… Read More

#Cancer Research #News

Blood cells
#Blood cancer #Clinical trials #EHA #Haematology #Oncology

Data highlights from EHA 2025

The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress.  Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More

#Cancer Research #News

#Combination therapy #Immunotherapy #Oncology #The Royal Marsden NHS Foundation Trust

Adding immunotherapy improves survival rates in anal cancer

Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust.    Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy.   Results… Read More

#Cancer Research #News

X-ray showing colon cancer
#Bowel cancer #Drug resistance #Oncology #Organoids #The Institute of Cancer Research

Scientists uncover mechanism behind drug resistance in bowel cancer

Scientists at The Institute of Cancer Research (ICR), London, have discovered what may cause some treatments to stop working in people living with bowel cancer.   The findings could help researchers use information about a person’s cancer to make better use of current treatments and develop more targeted… Read More

#Cancer Research #News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

#Combination therapy #Haematology #Lymphoma #Oncology #The Institute of Cancer Research

Drug combination treats B-cell lymphoma

Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.   For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More

#Cancer Research #Editor's Choice #News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer Research UK #Gene mutation #Oncology

New approach shows promise in aggressive breast cancers

A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.  In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More

#Cancer Research #News #Trending News

Cancer cells
#Artificial intelligence (AI) #Oncology #Parse Biosciences #Single-cell analysis #Wellcome Sanger Institute

Cancer plasticity atlas will help predict drug response

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich has announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies.   The collaboration will catalyse an ambitious future phase to… Read More

#Cancer Research #News

#Cancer research #Parabilis Medicines #Prostate cancer #Toxicology

Cracking the ERG code in prostate cancer

Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this?   JH: ERG… Read More

#Cancer Research #Exclusive Content

Theranostic radiopharmaceuticals
#Oncology #Radiochemistry #Radiopharmaceuticals

New standard ensures accurate dosing of radiopharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed the first US standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs.  The new standard, which is tied to the International… Read More

#Cancer Research #News

Neuroendocrine tumours
#ASCO #Clinical trial #Oncology #Perspective Therapeutics #Radiopharmaceuticals

Perspective shares positive responses in NETs at ASCO

Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.  The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More

#Cancer Research #News

Breast cancer
#ASCO #AstraZeneca #Breast cancer #Oncology #The Institute of Cancer Research

Camizestrant reduces risk of breast cancer progression by 56%

Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.  The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More

#Cancer Research #News #Trending News